Genomic Answers for Children’s Health Act of 2026

The Genomic Answers for Children’s Health Act of 2026 (HR7118) was introduced in the House of Representatives on January 15, 2026, and subsequently referred to the House Committee on Energy and Commerce. This bill seeks to amend title XIX of the Social Security Act to explicitly clarify that whole genome and whole exome sequencing for children with certain medical needs, such as genetic disorders, rare diseases, or conditions of unknown origin, will be covered under the Medicaid program. This legislative action is currently in its early stages, having only been introduced and referred to committee. This bill does not authorize a specific dollar amount but rather mandates coverage for a specific medical service. By clarifying and mandating Medicaid coverage for whole genome and whole exome sequencing, the bill establishes a new, guaranteed revenue stream for companies providing these services. The funding mechanism would be through the existing Medicaid program, where states, with federal matching funds, would be required to cover these diagnostic tests. This represents an expansion of the addressable market for genomic sequencing and bioinformatics within the Medicaid system, directly benefiting companies involved in providing sequencing technology, reagents, and data analysis services. Structural beneficiaries of this bill, if it progresses, include companies specializing in genomic sequencing and related bioinformatics. Companies such as Illumina ($ILMN), a leader in sequencing technology; Thermo Fisher Scientific ($TMO), which offers a broad range of life science solutions including sequencing instruments and consumables; Pacific Biosciences of California, Inc. ($PACB), known for its long-read sequencing platforms; Bionano Genomics, Inc. ($BNGO), focusing on optical genome mapping; and Fulgent Genetics, Inc. ($FLGT), a provider of genetic testing services, are positioned to see increased demand for their products and services. The bill's current status is early stage, having only been referred to committee, indicating a significant legislative path ahead. Looking at recent market data, Illumina ($ILMN) is currently at $127.74, showing a 7-day change of +5.74% and a 30-day change of -0.39%. Thermo Fisher Scientific ($TMO) is at $488.19, with a 7-day change of +1.7% and a 30-day change of -5.91%. Pacific Biosciences of California, Inc. ($PACB) is trading at $1.42, with a 7-day change of +12.7% and a 30-day change of -6.58%. Bionano Genomics, Inc. ($BNGO) is at $1.15, with a 7-day change of +1.77% and a 30-day change of +1.77%. Fulgent Genetics, Inc. ($FLGT) is at $16.42, with a 7-day change of +5.05% and a 30-day change of +15.23%. The recent positive 7-day changes for these companies, particularly PACB, ILMN, and FLGT, suggest some positive momentum in the sector, though the 30-day changes are mixed. The next legislative steps for HR7118 involve committee consideration, including potential hearings and markups. If approved by the Committee on Energy and Commerce, it would then proceed to a vote in the full House of Representatives. If passed by the House, it would then move to the Senate for similar consideration. Given its early stage, the timeline for potential enactment is uncertain and could extend over several months or longer.